Braf mutant study. The introduction of targeted agents for .



Braf mutant study. Jun 16, 2021 · Clinical observations indicate that colorectal cancer patients harboring the BRAF V600E mutation have a worse prognosis than BRAF wild type patients. May 30, 2025 · This result led to accelerated Food and Drug Administration approval of this investigational combination therapy for BRAF V600E–mutated metastatic colorectal cancer, including as first-line Jan 25, 2025 · Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. This study aimed to exam the impact of dabrafenib and Nov 14, 2022 · BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). BRAF V600E mutated NSCLC treated with chemotherapy have been widely reported to be associated with worse outcomes when compared to those without a mutation. Apr 16, 2022 · Our real-life multicenter study on 44 BRAF mutant NSCLC responds to the urgent need to characterize this subset of patients in-depth, potentially offering new valuable biological and clinical insights. Among the two broad types of lung cancer, non-small cell lung cancer accounts for 85% of the cases. 1%. Dabrafenib plus trametinib was found to have robust antitumor activity in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for Apr 12, 2024 · TRIDENTE trial: a phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer Jan 14, 2022 · Primary analysis of COMBI-i, a phase 3 trial of PD-1 + BRAF + MEK inhibition in BRAF-mutant melanoma. We highlight the evolving treatment landscape and emerging strategies for this molecularly distinct subtype. Nov 24, 2014 · The vast majority of patients who were included in this study 9 seem to have also been evaluated in this group's previous study 7 that examined the relationship between BRAF mutation status and PTC-related mortality. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The study aims to enroll 300 patients (pts) from 124 sites, treated according to the label. Methods In this study, 301 patients with pathologically confirmed colorectal cancer were retrospectively enrolled, comprising 225 from Centre I (73 mutant and 152 wild-type) and 76 from Centre II (36 mutant and 40 wild Feb 1, 2025 · In clinical practice, BRAF mutation testing strategies are dramatically impacted by a lack of harmonization and standardization, both in the pre-analytical and analytical phases, which can result in BRAF -mutated patients not receiving the most appropriate therapy at recurrence. 12 A study evaluating the role of nivolumab in monotherapy in 74 MSI patients showed an ORR of 25% in BRAF-mutant tumors, 27% in KRAS mutated, and 41% if both were wild type [27]. We undertook a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–positive nonmelanoma cancers. KRAS and BRAF mutations are well-established predictive and prognostic factors in metastatic colorectal cancer; however, their impact in the adjuvant setting has not yet been established. See the article " Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study " in J Clin Oncol, volume 37 on page 1460. Mar 31, 2025 · In this study, using liquid biopsy, we found that the highest frequency of class 1 BRAF alterations is present in cholangiocarcinoma while Class II/III BRAF alterations are more common in hepatocellular cancer and gastroesophageal cancer. Apr 28, 2020 · BRAF mutation is an oncogenic driver gene in non-small cell lung cancer (NSCLC) with low frequency. Sep 19, 2023 · Methods For this multicenter cohort study, we identified 515 BRAF mut patients with resected stage III melanoma who were treated with PD-1 inhibitors (anti-PD1) or TT in the adjuvant setting. Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600–mutant LGG; other cohorts will be reported elsewhere. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from pre … Jul 12, 2012 · Although further study will be needed to understand the individual role of BRAF inhibitors versus MEK inhibitors in patients who have melanoma with a V600E or V600K BRAF mutation, both classes of The landscape of BRAF-mutant NSCLC is further explored in a Phase II study designed to assess the efficacy and safety of neoadjuvant and adjuvant targeted therapy. 21 months compared to 20. The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab. We performed a meta-analysis of adjuvant phase III trials in Nov 1, 2023 · Two reports from the phase II TADPOLE trial show the benefit of molecularly targeted therapy in pediatric brain tumors with BRAF mutations. Feb 15, 2024 · In this study, 98 people with BRAF V600E-mutant metastatic NSCLC were treated with the combination of encorafenib and binimetinib (called encorafenib plus binimetinib in this summary). Sep 14, 2024 · Findings from two studies presented at the ESMO Congress 2024 (Barcelona, 13–17 September) confirm the validity of targeting BRAF and MEK in BRAF V600E-mutant non-small cell lung cancer (NSCLC) for which two combinations of targeted agents – dabrafenib–trametinib and encorafenib–binimetinib – are now approved in Europe. We investigated whether BRAF mutation class differed according to clinical, genomic, and transcriptomic variables in cancer patients. We conducted a retrospective multicenter study in Chinese patients with NSCLC harboring Nov 1, 2022 · Further limitations preventing optimal management of BRAF-mutant malignancies are that treatments of non-V600 BRAF mutations have been less profound and combination therapy is likely necessary to overcome resistance mechanisms, but multi-drug regimens are often too toxic. Jan 25, 2025 · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center. et al. We aimed to assess the prognostic and predictive impact of BRAF mt on the efficacy of targeted therapies with first-line chemotherapy Feb 6, 2024 · This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from previous real-world studies and clinical trials, and stressing the urgent need for more effective treatment Sep 27, 2022 · Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600 -mutant metastatic melanoma, leading to broad regulatory approval. investigator’s choice of irinotecan (IRI) or FOLFIRI + CETUX (control) in patients with BRAF V600E‒mutant mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. 23 This analysis revealed that the hazard ratios of patients treated with EGFR-blocking antibodies (cetuximab or panitumumab) were not depending on the BRAF mutation status for Dec 10, 2018 · Vemurafenib demonstrated evidence of durable antitumor activity in some patients with <i>BRAF</i><sup>V600</sup>-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. We did not observe the detrimental effect of BRAF mutations on overall survival in these tumor types. 73 Further research is needed to evaluate predictive significance of BRAF mutation status in anti‐EGFR therapy. Several resistance mechanisms have been identified that have led to the development of different treatment strategies, which have shown encouraging activity in early clinical trials. Apr 6, 2023 · Patients were eligible after at least 2 prior lines of therapy including an immunomodulatory drug and a proteasome inhibitor if a BRAF V600E mutation was confirmed by immunohistochemistry using a mutation-specific antibody and DNA sequencing in ≥50% of MM cells. Jun 1, 2025 · In this study, we present an ML-based US radiomics approach capable of predicting the mutation status of BRAF V600E, TERT promoter, or the coexistence of BRAF V600E and TERT promoter mutations in PTC patients. Sep 12, 2025 · BRAF V600E-mutant metastatic colorectal cancer, a rare subtype with poor prognosis, has historically carried limited treatment options. Sep 23, 2024 · Prespecified exploratory genomic and transcriptomic profiling of tumor tissues and circulating tumor DNA from patients with BRAF-V600E-mutant metastatic colorectal cancer who participated in the Apr 14, 2023 · Subbiah, V. However, the median survival in stage IV disease was shorter in patients with BRAF-mutant melanoma and not treated with a BRAF inhibitor than in the wild type (WT) situation [8, 9]. The primary objective was overall response rate (ORR) by independent review by Response Assessment in Neuro-Oncology criteria. Feb 21, 2024 · Agents developed to target BRAF alterations, particularly BRAFV600E, have significantly improved outcomes for patients with melanoma and colorectal cancer, among others. The primary Nov 1, 2023 · BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time. Notably, a pilot trial did report that a subset of BRAF mutant patients can develop new RAI enhancement in metastatic lesions with the BRAF inhibitor dabrafenib (Novartis) (19). 6, 7 BRAF mutation (MT) results in constitutive activation of downstream kinases, resulting in cellular proliferation and survival. Nov 9, 2017 · Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. Nov 24, 2021 · In The Lancet Oncology, Patrick Y Wen and colleagues present interim results from the Rare Oncology Agnostic Research (ROAR) study,1 an ongoing phase 2, open-label, single-arm, multicentre basket trial of targeted therapies in BRAF-mutant cancers, showing positive results for dabrafenib plus trametinib in patients with high-grade glioma and low-grade glioma. 14 In a population-based study that could better reflect the true incidence, 12% of the patients had BRAF -V600E mutant May 15, 2019 · We appreciate the interest generated by our study on the impact of BRAF functional class on clinical outcomes in patients with NSCLC. The primary endpoint was met, with an objective response rate (ORR) by independent review radiology (IRR) of 75% in treatment-naïve and 46% in previously treated pts. As anaplastic thyroid cancer (ATC) is a rare and aggressive form of thyroid cancer, this study was conducted to provide a view Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine Sep 28, 2024 · Background The prevalence of genetic mutations in thyroid cancer varies significantly among different ethnic backgrounds. Patients received a combination of the BRAF inhibitor encorafenib, the anti-EGFR antibody cetuximab, and the MEK inhibitor binimetinib. Mutant BRAF is a bona fide “driver oncogene”, since mutant BRAF inactivation often induces cancer cell toxicity, which indicates the establishment of an acquired dependency of tumor cells on oncogenic, mutant forms of BRAF [18]. Unfortunately, 80% patients treated will progress by 5 years follow-up. A. The introduction of targeted agents for Jan 27, 2021 · The study was a randomized, three-arm, phase III study that evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan plus cetuximab or FOLFIRI (folinic acid, fluorouracil, and irinotecan) plus cetuximab in 665 patients with BRAF V600E–mutant mCRC whose disease had progressed after one or two Jan 26, 2024 · Although the majority of patients with BRAFV600E -mutant tumours derive clinical benefit from BRAF inhibitor-based combinations, resistance to treatment develops in most. 1 Briefly, PHAROS (NCT03915951) is an ongoing, single-arm, open-label, multicenter, phase 2 study evaluating antitumor activity and safety of encorafenib plus binimetinib in treatment-naive or previously treated adult patients with BRAF V600E-mutant mNSCLC. This study aimed to assess survival outcomes in patients with extrahepatic mCRC harboring mBRAF who underwent upfront metastasectomy, compared with patients with BRAF mutation occurs in 5%–10% of metastatic colorectal cancers (mCRCs). Targeting BRAF by selective inhibitors has This BRAF V600 Mutation and Glioma study at University of California Health ends December 2031. In this study, MSI-H cases had a better prognosis than MSS cases in BRAF V600E mutation, potentially reflecting the survival benefit of immune checkpoint inhibitors in later-line chemotherapy for MSI-H patients [33]. Feb 27, 2021 · In this review, we will discuss the prevalence of BRAF mutations across human cancers and evidence on the efficacy and safety of current management strategies for various BRAF-mutant solid tumors. Jun 30, 2011 · Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. Methods: Patients diagnosed with BRAF V600E mutant-mCRC between February 2014 and January 2022 in five hospitals were enrolled. 7% in patients with ACRC, and there was no BRAF mutation in patients with ECRC. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. Patients with BRAF mutant mCRC exhibit a specific metastatic pattern and poor prognosis. BRAF mutations confer constitutive activation of MAPK signalling. Jun 28, 2022 · In this study, the BRAF mutation rate was 4. We measured the diagnostic BRAF mutation affects the biological characteristics and microenvironment of the tumor during the development of colorectal cancer. Conclusions: To the best of our knowledge, this is the first retrospective study exploring BRAFi treatment effectiveness to BRAF mutated solid tumors for Chinese patients. The BRAFV600E Mar 15, 2018 · This was the first study to examine such a large cohort of non-V600 BRAF mutants and convincingly establish that non-V600 mutant tumors represent a biologically distinct group of tumors from class Sep 20, 2023 · Detection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. Inhibition of Apr 7, 2021 · The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab. Dec 1, 2022 · This study is, to date, the largest real-world analysis of patients with BRAF V600E-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. BRAF gene is mutated in 40–50% of melanomas and its role in melanoma development is paramount. Improved understanding of the biology of the BRAF oncogene has led to the development of targeted therapies that have paved the way for a paradigm shift in managing this disease. Nov 29, 2024 · Systemic therapies for BRAF -mutant melanoma with BRAF-MEK inhibitors and immunotherapy provided an important survival benefit and have dramatically changed routine management [18]. However, despite Jul 26, 2021 · In the present study, we analyzed the differences of immune microenvironments between BRAF mutated and BRAF wild-type colon cancer utilizing datasets from The Cancer Genome Atlas and Gene Expression Omnibus and confirmed the findings by tissue specimens of patients. May 31, 2023 · Here we present the updated study design. We report updated survival analysis of a phase 2 study (NCT01336634) with a minimum of 5-year follow-up and updated genomic data. This study aimed to describe the prognosis of BRAF V600E mutant-mCRC, analyze the recurrence pattern Apr 28, 2020 · BRAF mutation is an oncogenic driver gene in non-small cell lung cancer (NSCLC) with low frequency. gov identifier: NCT01657591], with plans for a triple combination with BRAF and MEK inhibitor therapy. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials. Jun 1, 2022 · BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this tumor type on the basis of prognostic and predictive implications. The study of the genetic alteration has facilitated the development of targeted Oct 23, 2018 · BRAF Inhibition in BRAFV600 -Mutant Gliomas: Results From the VE-BASKET Study The following represents disclosure information provided by authors of this manuscript. Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study Chenxing Zhang, PhD,a Chenyue Zhang, PhD,bJiamao Lin, PhD,cZhenxiang Li, PhD,c Haiyong Wang, MDc,* May 9, 2023 · The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the result of more than 20 years of extensive research into BRAF mutations in Dabrafenib and trametinib combination has transformed oncology care in BRAF V600–mutated cancers. Dabrafenib and trametinib has been the standard treatment for the patients with BRAF mutation based on phase II study. 10 However, resistance to single This study is, to date, the largest real-world analysis of patients with BRAF<sup>V600E</sup>-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. In another recent study, cells developing resistance to the drug triplet maintained both the BRAF V600E mutation and KRAS mutation (G12D or G13D) [58], demonstrating that the coexistence of both mutations confers greater treatment resistance to the tumor. Dec 8, 2023 · However, those with the BRAF mutation experienced significantly poorer outcomes, with a median survival of only 8. In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. Historically, first-line treatment of 6 days ago · Location: China Study ID: NCT06603376 The IMPROVEMENT-2 trial is testing whether adding vemurafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) to a backbone of liposomal irinotecan–based FOLFIRI chemotherapy can improve outcomes for patients with BRAFV600E-mutant advanced colorectal cancer in the first-line setting. We aimed to determine whether mutant BRAF expression in melanoma differs according to age, sex, and melanoma-specific survival. Mar 19, 2024 · The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer, and is associated with poor prognosis. 05). Jan 26, 2025 · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 The PICCOLO study identified an increased risk of mortality for BRAF‐mutated patients undergoing treatment with irinotecan and panitumumab compared with irinotecan alone. Additional data from a separate arm of the BREAKWATER study evaluating BRAFTOVI in combination with cetuximab will also be presented at ASCO. May 15, 2025 · Purpose The aim of this study was to develop and validate CT venous phase image-based radiomics to predict BRAF gene mutation status in preoperative colorectal cancer patients. Dec 25, 2023 · This study aimed to investigate the relationship between the allele frequency (AF) of the BRAF V600E mutation and the histopathological features of papillary thyroid cancer (PTC), with a focus on its aggressive behavior. This study is, to date, the largest real-world analysis of patients with BRAF V600E -mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. Jul 25, 2022 · Tara Mitchell, MD, discusses treatment options for a patient whose metastatic melanoma has a BRAF V600E mutation and has spread to the central nervous system. Sep 28, 2024 · This large single-center study reveals that BRAF V600E is highly prevalent in the Han Chinese population and demonstrates BRAF V600E mutation testing has high diagnostic accuracy and its strong association with the progress of aggressiveness in PTCs and a higher probability of recurrence. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. Jun 2, 2025 · Updated results from the BREAKWATER trial support encorafenib plus cetuximab and mFOLFOX6 as a new standard of care for patients with BRAF V600E-mutated, metastatic colorectal cancer, according to Jan 3, 2019 · This study represents the largest clinical analysis of BRAF-mutant lung cancer and the first clinical study to apply the new functional classification system. Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo. May 29, 2024 · A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification. We therefore agree that it is essential to develop alternative therapeutic strategies for this molecular subgroup. 6 days ago · Purpose The negative impact of the BRAF V600E mutation (mBRAF) on survival outcomes has been reported for metastatic colorectal cancer (mCRC), but the role of mBRAF testing in resectable extrahepatic cases remains unclear. Jun 18, 2019 · Epidemiology BRAF mutations are present in 5–15% of CRC, with a higher mutation rate in right-sided colon cancer. This Jul 12, 2023 · Eligible patients who had papillary craniopharyngiomas that tested positive for BRAF mutations, had not undergone radiation therapy previously, and had measurable disease received the BRAF–MEK Nov 1, 2012 · In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily Dec 17, 2021 · Results from a large study are expected to help determine the best treatment approach for some people with an advanced form of melanoma. Further limitations preventing optimal management of BRAF mutant malignancies are that treatments of non-V600 BRAF mutations have been less profound and combination therapy is likely necessary to overcome resistance mechanisms, but multi-drug regimens are often too toxic. Mar 5, 2025 · Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment. The combination of encorafenib plus binimetinib might be an important addition to the treatment options available to patients with BRAFV600 -mutant melanoma. BRAF gene mutations can cause normal cells to become cancerous. Jun 5, 2024 · Methods: This Phase II, multicenter, randomized, open-label, 2-arm study evaluated E+C vs irinotecan + cetuximab or FOLFIRI + cetuximab (control arm) in Chinese patients with BRAF V600E mutant mCRC whose disease progressed after 1 or 2 prior treatment lines in the metastatic setting. Apr 10, 2013 · Xing and coauthors conducted a retrospective study among 1849 patients in 7 countries to investigate the relationship between the BRAF V600E mutation and mortality related to papillary thyroid cancer. The study was approved by local ethics committees. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. The NCI-sponsored clinical trial, called DREAMseq, included people with metastatic melanoma whose tumors had a specific mutation in the BRAF gene, called V600. A BRAF genetic test looks for changes (mutations) in the BRAF gene. May 29, 2024 · BRAF mutation variant allele frequency is not an independent prognostic factor for survival with patients received BRAF inhibitor treatment (p>0. Apr 16, 2024 · This manuscript provides a review of BRAF-mutant metastatic NSCLC and the therapeutic landscape with particular emphasis on targeted therapies for the V600E mutation. Jan 19, 2024 · Background: BRAF mutations are classified into four molecularly distinct groups, and Class 1 (V600) mutant tumors are treated with targeted therapies. The present study aimed to investigate the clinical potential of BRAF V600E in a large group of homogenous Han Chinese patients. The lead-in included 29 patients from the phase 2 BEACON study who had BRAF V600–mutant metastatic CRC that had progressed after 1 or 2 prior regimens. Disease characteristics, treatment regimens, details on tumor recurrence, subsequent treatment management, and survival outcomes were collected within the prospective, real-world skin cancer registry Jun 4, 2025 · Full study design, methods, oversight, and statistical analyses were published previously. Although cross-trial comparisons Lung cancer is the leading cause of cancer related deaths. The BRAF MT is present in 60% of all melanomas but is present in < 10% of Nov 13, 2014 · We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation–positive melanoma to receive vemurafenib and cobimetinib (combination May 4, 2021 · This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort. Over the past decade, BRAF V600E and other molecular markers have emerged as potential risk factors for PTC-related death and PTC recurrence. We conducted a clinical trial to evaluate how effectively vemurafenib can mediate the clinical and molecular redifferentiation of BRAF mutant RAIR thyroid cancers. BRAF mutat … In this study of a cohort of 524 patients with metastatic CRC, 57 (11%) patients were found to harbor a BRAF mutation (55 BRAF V600E, 1 BRAFG593D, 1 BRAFQ609X). Apr 23, 2025 · The study included 870 adults with resected, BRAF V600-mutant, stage III melanoma who were enrolled in the phase 3 COMBI-AD trial. Targeted therapy with BRAF and MEK Apr 1, 2025 · This study supports the suggestion that class 3 BRAF mutations amplify existing Ras signaling in a two-mutation model and that the enhancement of weak/atypical Ras mutations may suffice for tumorigenesis, with potentially clinically important heterogeneity in the class 2/3 subgroup. The primary Explore this phase 3 study to learn about progression-free survival and overall survival in patients receiving a BRAF V600E mutant kinase inhibitor + EGFR inhibitor + chemotherapy for BRAF-mutant Nov 1, 2023 · BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time. May 1, 2025 · BRAF mutation affects the biological characteristics and microenvironment of the tumor during the development of colorectal cancer. Methods: The BEACON CRC Study (NCT02928224) was a multicenter, randomized, open-label, 3-arm, phase 3 study to evaluate ENCO+CETUX with/without BINI (triplet or doublet combination) vs. Treatment approaches vary depending on whether or not the metastases are initially resectable. Oct 1, 2018 · BRAF–MEK inhibitor combinations have improved progression-free and overall survival in patients with BRAF -mutant melanoma but with treatment-limiting and dose-limiting toxicities. Jan 10, 2022 · Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort of the phase II Rare Oncology Agnostic Research (ROAR) basket study. Methods From 2018 to 2021, 6232 thyroid disease patients who underwent thyroidectomy at our hospital were enrolled. Nov 24, 2021 · Dabrafenib plus trametinib showed clinically meaningful activity in patients with BRAFV600E mutation-positive recurrent or refractory high-grade glioma and low-grade glioma, with a safety profile consistent with that in other indications. Should the relationship BRAF mutation is one of the targetable oncogenic driver mutations in non-small-cell lung cancer (NSCLC). Evolving approaches, including targeted combinations and investigational immunotherapy-based strategies, offer potential to improve outcomes. May 29, 2024 · It represents the first NIS to investigate the real-world use of E+C in BRAF V600E-mutant metastatic colorectal cancer in Germany, Austria and Switzerland. This study underscores the significance of early BRAF testing at the time of colorectal cancer diagnosis. There is an ongoing phase I study of vemurafenib with XL888 in patients with advanced BRAF V600-mutant melanoma [ClinicalTrials. The data of patients with NSCLC harboring BRAF mutations is rare. Recently, such a study was achieved by doing a meta-analysis that grouped eight cohorts consisting of 351 BRAF -mutant patients, including BRAF wild-type patients. However, despite Jan 4, 2022 · BRAF mutations were concentrated in the kinase domain, with 80% a single valine to glutamic acid hotspot mutation at codon 600 within the activation segment (BRAF V600E, initially mischaracterized as V599E). The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Rescreening of a large subset of the cohort revealed four tumors with coincident RAS and BRAF mutations, all of which were non-V600 mutations. Seventy-nine patients histologically diagnosed with UC of the bladder and/or urethra between 2006 and 2019 were included in this retrospective single-centre-study. Aug 10, 2017 · One study proposed that mutant BRAF had no impact on the disease-free interval from diagnosis of the culprit tumor to first distant metastasis. Jan 25, 2025 · Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis. Primary analysis of the PHAROS study showed efficacy and safety of encorafenib (enco; BRAF inhibitor) plus binimetinib (bini; MEK inhibitor) in patients (pts) with BRAF V600E-mutant mNSCLC. Mutations in BRAF can result in unbridled activation of downstream kinases with subsequent uncontrolled cellular growth that formulate the basis for oncogenesis in multiple tumor types. Therefore, it is noteworthy that BRAF mutation status has emerged as a more robust prognostic factor for PTC recurrence than for PTC-related mortality. 2 This is the first retrospective study to assess the treatment of BRAF V600E -mutant mCRC in routine clinical practice across Europe between 2016-2020, with the aim of defining Oct 13, 2023 · Christina Wu, MB, BCh, MD, shares data from the phase 3 BREAKWATER trial, which assesses first-line targeted treatment strategies for patients with BRAF V600E-mutant metastatic colorectal cancer. The primary study objective is to assess the 1-year OS rate. This study aimed to systematically evaluate the impact of BRAF gene mutations on the remodeling of th … In this study, we recruited patients from various races into a single study and performed statistical tests to compare the KRAS and BRAF mutation rates across races. … Nov 4, 2024 · BRAF is an important target for the treatment of various solid tumors, and targeted combination therapies, represented by BRAF inhibitors, have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors. Oct 14, 2024 · In this bioinformatic data analysis, systematic review, and meta-analysis, we characterize BRAF K601E mutant TCs by comparing the mutation prevalence, clinicopathologic variables, and outcomes to BRAF V600E mutants and BRAF wild-type tumors. Because of their rarity, the clinical backgrounds and outcomes of cytotoxic chemotherapy or immunotherapy remain unclear, and no targeted therapies are approved for BRAF non–V600E-mutant NSCLC. We report an updated analysis describing the efficacy and safety of dabrafenib plus Mar 1, 2025 · Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (m… Approximately 50% of melanomas contain BRAF mutations; the effects on survival are unclear. Methods: BREAKWATER is an ongoing, open-label, multicenter, randomized, phase 3 study evaluating 1L EC ± CT vs SOC CT alone in pts with BRAF V600E-mutant mCRC. Based on these results, the FDA Abstract BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. Feb 25, 2025 · The BREAKWATER trial was designed as an open-label, multicenter, phase III study to evaluate the addition of encorafenib and cetuximab to standard mFOLFOX (EC-FOLFOX) in untreated BRAF V600E–mutant metastatic colorectal cancer. This study was conducted The CAPSTAN study, which is the largest real-world study of its kind, has very recently been published in ESMO OPEN and described the treatment patterns of BRAF V600E -mutant mCRC in a real-world setting across Europe. 03 months for those without the mutation. Secondary objectives included ORR by investigator determination, duration of response (DOR), progression-free survival, overall survival (OS), and safety. Nov 13, 2019 · Based on these data, Pfizer, which sponsored the study, has submitted an application to the Food and Drug Administration (FDA) to approve the doublet therapy to treat patients with BRAF V600E-mutant metastatic colorectal cancer. However, this condition is very rare, as previously mentioned [15]. This study aimed to systematically evaluate the impact of BRAF gene mutations on the remodeling of the CRC immune microenvironment, with a particular focus on their effects on the maturation and Jul 21, 2022 · Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Thus Feb 27, 2023 · The BRAF mutation subgroup resulted in the TRIBE2 study exhibiting no survival benefits from FOLFOXIRI + bevacizumab treatment [29]. “The risk of death for patients with BRAF V600E -mutant metastatic colorectal cancer is more than double compared to those with no known mutation,” said Michael Sapienza, Chief Executive Officer, Colorectal Cancer Alliance. This study aimed to describe the prognosis of BRAF V600E mutant-mCRC, analyze the recurrence pattern Jul 29, 2016 · The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAFV600 -mutant advanced melanoma, as previously reported in the coBRIM study. Feb 24, 2023 · BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival. However, the prevalence, real-world treatments and clinical outcomes are rarely reported in Chinese BRAF-mutated NSCLC patients. Feb 4, 2020 · Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Methods: STARBOARD (NCT04657991) is a phase III study with an initial safety lead-in (SLI) phase conducted to determine the Feb 1, 2013 · The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma. Dec 30, 2020 · The BRAF V600E mutation, a class 1 variant, is the best-understood alteration in the gene, but despite that, extensive pre-clinical and empiric study has been required to optimize combinatorial therapies in order to overcome bypass and downstream signaling induced by BRAF inhibitor monotherapy in tumors with this mutation. Jun 4, 2023 · Planchard D, Besse B, Groen HJM, et al: Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: Updated 5-year survival rates and genomic analysis. In our analysis, responses to standard first-line chemotherapy were not durable for patients with class II and III BRAF mutations. The research involved a retrospective Feb 23, 2012 · The previously reported phase 1 study with vemurafenib in patients with BRAF V600–mutant metastatic melanoma provided evidence that inhibition of the oncogenic MAPK pathway resulted in May 5, 2017 · Patients and methods This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. Ascierto Mar 27, 2024 · Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E -mutant metastatic non–small-cell lung cancer (NSCLC). The benefit of metastasectomy remains unclear, and the optimal first-line treatment is controversial. Aug 29, 2023 · This phase II study evaluated dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600–mutant pHGG. May 30, 2025 · in January 2025. Jul 21, 2022 · In a study published in 2020, researchers conducting the ROAR trial wrote that routine testing for the BRAF V600E mutation should be considered for all patients with biliary tract cancer. Oct 22, 2019 · Immunotherapy is beginning to show promise as an active therapy in BRAF mutated NSCLC in both V600E and non-V600E subtypes; however, this requires further study and clarification. Resistance to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) plus mitogen-activated protein kinase kinase (MEK) inhibition (BRAFi+MEKi) in BRAF V600E -mutant gliomas drives rebound, progression, and high mortality, yet it remains poorly understood. Mutations in BRAF gene will lead to cancer development and progression. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain … Nov 1, 2017 · Similarly, BRAF mutation may confer mCRC a worse prognosis and resistance to these therapies but at the same time a potential target for new drugs and combinations. Survival outcomes are heterogeneous in cases of mCRC with a BRAF mutation. In this review, we will discuss potential transcriptional networks that can mediate BRAF mutation signal to cause malignancy and disrupted gene regulations in the presence of BRAF mutation in several cancers (Table 1 and Table 2). We sought to determine whethe May 20, 2024 · Article Published: 20 May 2024 Clinical Studies Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated Aug 1, 2021 · The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab. Feb 1, 2025 · Only the IMspire150 study offers favorable data in terms of PFS for the administration of atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF (V600) mutation-positive melanoma [17]. This study aimed to describe the prognosis of BRAF V600E mutant-mCRC, analyze the recurrence pattern in resectable patients, and explore the optimal first-line treatment for unresectable patients. BRAFV600E testing could potentially be adopted in clinical practice for patients with glioma. Learn about the mutation, the types of cancer it can cause and the treatments available. A combination of nivolumab with ipilimumab obtained similar results [77]. In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies. The optimal Nov 1, 2023 · BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time. A total of 638 patients who Abstract Lessons learned: This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort. In 2020, a meta-analysis of five randomized trials comparing FOLFOXIRI + bevacizumab to doublet chemotherapy + bevacizumab failed to show any advantage of FOLFOXIRI + bevacizumab in subgroup analyses [30]. Spectrum of BRAF inhibition has evolved from being melanoma-specific to being a pan-cancer target. In non-small cell lung Apr 2, 2025 · Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study Mar 6, 2025 · The size of BRAF-V600E mutated or right-lobe located nodules was significantly larger than that in the control group (p = 0. “These Apr 15, 2025 · Study population Patients treated with adjuvant anti-PD-1 or BRAK/MEK inhibitors, 18 years and older, with BRAF -mutated stage III and IV melanoma following complete resection and diagnosed Nov 17, 2017 · Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Oncology providers continually seek ways to improve cancer treatment. We conducted a retrospective multicenter study in Chinese patients with NSCLC harboring BRAF mutations between Jan 2017 and Jul 2019. Learn more. Dabrafenib and trametinib would offer a new therapeutic option for rare cancers, such as high-grade gliomas, biliary tract cancer, and thyroid cancer. Effective treatment has not been established for Class 2/3 or BRAF Fusions. Tumor-associated lymph nodes are the key sites of immune response. A 57-year-old woman with ACRC had both KRAS and BRAF mutations in this study. BRAF V600E mutation is proved critical in the progression and invasion of thyroid cancer, and as a prognostic biomarker. The large majority (about 90%) of BRAF mutations occur at amino acid 600; the majority are BRAFV600E mutations and less frequently BRAFv600K, V600D and V600M. Approximately 620 pts will be enrolled in the phase 3 portion and an additional 135 in cohort 3 (Table). gov identifier: NCT01909453). Apr 23, 2025 · Combined BRAF and EGFR inhibition enriched for EECs in all BRAF mutant CRC models tested. Combinations of BRAFi/MEKi with CPIs may further improve outcomes and could offer additional treatment strategies. While developing new drugs is one approach, another critical strategy is optimizing Agents have been explored either as monotherapy or in combination with MEK inhibition in BRAF V600-mutant pan-cancers and with EGFR inhibition in colorectal cancer. An observational study evaluated more than 1000 patients with metastatic melanoma with BRAF V600 mutation and treated in the first line with either BRAFi/MEKi or ICIs (PD-1 single agent or combined PD-1/CTLA-4 antibodies), included in the EUMelaReg treatment registry [55]. Anaplastic thyroid cancer (ATC) is a rare but lethal thyroid cancer. Aug 5, 2023 · The benefit of first-line ICI was demonstrated in both studies with Secombit study showing the "sandwich" approach to have similar effect. The purpose of our study is to characterize BRAF mutations in myeloid neoplasms using a next-generation sequencing (NGS) panel based on the Aug 20, 2015 · BRAF V600 mutations occur in various nonmelanoma cancers. Aug 21, 2023 · The NEXUS trial is a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant CRM. Sep 19, 2024 · Therapy targeting the BRAF-MEK cascade created a treatment revolution for patients with BRAF mutant advanced melanoma. BRAF non-V600E mutations occur in 1% to 2% of NSCLCs. BRAF V600E is a protooncogene mutation that encodes an upregulated active form of the B-Raf protein leading to an overactive MAP kinase signaling pathway and contributing to tumorigenesis [5, 6]. BRAF alterations in colorectal cancer are classified into three functional categories on the basis BRAF-mutant CRC is a complex disease subtype that warrants novel translational approaches and clinical trials. The development of agents targeting mutant BRAF was heralded by the approval of BRAF inhibitor vemurafenib for BRAFV600E -mutated melanoma after encouraging survival benefit was demonstrated. Jun 26, 2024 · This study indicates that dabrafenib plus trametinib could be considered as the optimal treatment option for Chinese patients with NSCLC harbouring BRAF V600 mutations. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from previous real-world studies and clinical trials, and stressing the urgent need for more effective treatment Aug 23, 2023 · NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases Aug 31, 2023 · This study reported promising efficacy against BRAF V600-mutant tumours. “FDA is currently reviewing the application and we expect to hear [a decision] shortly,” said Dr. Abstract Drs. 0156), and patients with a BRAF V600E mutation were considerably younger than those with wild-type BRAF. In an editorial, Cappola and Mandel discuss molecular testing in thyroid cancer. Jan 25, 2025 · In this study, MSI-H cases had a better prognosis than MSS cases in BRAF V600E mutation, potentially reflecting the survival benefit of immune checkpoint inhibitors in later-line chemotherapy for MSI-H patients [33]. The results can guide treatment for melanoma and certain other cancers. This study addresses the urgent need to develop treatments for BRAFi+MEKi-resistant glioma using preclinical mouse models and patient V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by BRAF gene, plays critical roles in cell signaling, growth, and survival. Melanoma is caused by a variety of somatic mutations, and among these mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a critical diagnostic biomarker in clinical practice. Notably, the overall response and median progression-free survival recorded with combination dabrafenib plus trametinib were higher when compared indirectly with dabrafenib monotherapy, used in cohort A of this study. All patients with metastatic melanoma should undergo sequencing of the BRAF gene to identify noncanonical BRAF mutations that may indicate benefit from treatment with trametinib. An observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life. Abstract Background First-line therapeutic strategies for patients with BRAFV600E -mutated (BRAF mt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). A preclinical study of melanoma with BRAF -mutation indicated that cells with the acquired upregulation of EGFR expression were induced by using a BRAF inhibitor, but these cells became vulnerable when the treatment was ceased. The FDA accelerated approval of dabrafenib in combination with trametinib for unresectable or metastatic BRAF V600E solid tumors is the culmination of two decades of research into the landscape of BRAF mutations in human cancer, the biochemical Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. May 4, 2021 · This study suggests that trametinib has significant clinical activity in non‐V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort. Jun 6, 2016 · To the best of our knowledge, this trial is the first to assess combination BRAF and MEK inhibition in patients with BRAFV600E -mutant NSCLC. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free survival, compared to dabrafenib monotherapy, in a Phase II study and has received Aug 21, 2023 · Methods: The NEXUS trial is a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant CRM. May 28, 2021 · BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). Jul 5, 2023 · Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease. In previous trials, dabrafenib (both as monotherapy and in com We describe the design of PHAROS, a clinical trial investigating encorafenib (mutant BRAF inhibitor) combined with binimetinib (MEK inhibitor) in people with BRAFV600 -mutant NSCLC that had spread to other parts of the body (‘metastatic disease’). Sep 1, 2024 · BRAFV600E-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates. Current data advices for immunotherapy based regiments in patients with BRAF mutant melanoma or, possibly, sandwich approach. Jul 1, 2022 · Lung cancer harbouring BRAF mutations accounts for 4% of all non-small cell lung cancer (NSCLC) cases, identifying a relevant subset of patients that … This paper provides an overview on the pathogenic ramifications of mutant BRAF signaling, the latest molecular testing methods to detect BRAF mutations, and the most recent clinical data of BRAF pathway inhibitors in patients with melanoma and BRAF mutations. Mar 20, 2019 · Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study Patients and methods This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. Kopetz. This study aimed to describe the prognosis of BRAF V600E mutant-mCRC, analyze the recurrence pattern Jun 12, 2025 · POLARIS was a study to evaluate different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. This study investigates the relationship between BRAF (variant V595E) mutation status and overall survival in UC-bearing dogs. Although these therapies have shown substantial efficacy in clinical trials, their sustained effectiveness is often challenged by the tumor microenvironment, which is a highly Aug 21, 2023 · Methods: The NEXUS trial is a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant CRM. The first part, known as the safety lead-in, looked Nov 4, 2024 · BRAF is an important target for the treatment of various solid tumors, and targeted combination therapies, represented by BRAF inhibitors, have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors. Additionally, EECs and other secretory cell types were enriched in a subset of BRAFV600E CRC patient samples following targeted therapy. The ROAR and NCI-MATCH studies included a total of 131 adult patients with 24 types of BRAF V600E mutation-positive tumors. Jan 27, 2021 · The BRAF gene encodes for a serine or threonine protein kinase associated with the mitogen-activated protein kinase pathway, an essential pathway in the carcinogenesis of multiple cancers. 12, 13 In a report comprising 2530 patients with mCRC included in three randomized trials (COIN, FOCUS, and PICCOLO), the prevalence of BRAF mutations was 9. In this article, learn more about Apr 3, 2024 · BRAFV600E-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates. Methods: Using the AACR GENIE (v. Long challenged with targeted Jul 1, 2017 · These data demonstrate that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting. May 30, 2025 · First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free survival, compared to dabrafenib monotherapy, in a Phase II study and has received Sep 12, 2024 · Over the past several decades, advancements in the treatment of BRAF-mutant melanoma have led to the development of BRAF inhibitors, BRAF/MEK inhibitor combinations, anti-PD-1 therapy, and anti-CTLA4 therapy. Jun 4, 2023 · The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E/K -mutant metastatic melanoma. 1244O - KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma P. Jan 25, 2025 · These findings highlight distinct clinical and prognostic profiles for BRAF V600E and non-V600E mutations, while treatment choice appears to have limited impact on survival in these subgroups or RAS/BRAF wild-type cases. Dabrafenib combined with trametinib was superior to chemotherapy in low-grade gliomas and yielded favorable responses in a single-arm study of high-grade ones, … Background: BRAF inhibitors plus MEK inhibitors (BRAFi/MEKi) and immune checkpoint inhibitors (CPIs) are approved for BRAF V600-mutant advanced melanoma. This review aims to summarize the impact of BRAF mutation in early and advanced CRC as well as the current management and future perspectives in BRAF mutant (BRAF -mt) mCRC. Apr 6, 2021 · The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab. BRAF mutations are rare in myeloid neoplasms and are reported to be associated with poor treatment outcomes. cxv mdfigy alez dyodh wgk qftig ifkh2os wkn1g9k ooj 6hva